The characteristics of Waldenstrom macroglobulinemia that distinguish the disease from other types of lymphomas.

An overview of the types of biomarkers that play a role in the manifestation of Waldenstrom macroglobulinemia.

The criteria used by hematologists and oncologists to guide decisions to initiate therapy for Waldenstrom macroglobulinemia vs monitor patients with active surveillance.

What pharmacists need to know about the adoption of novel targeted therapies for Waldenstrom macroglobulinemia into regular clinical practice.

Recommendations for classifying and treating patients with progressive Waldenstrom macroglobulinemia.

The top considerations of hematologists and oncologists when selecting first-line treatment for patients with Waldenstrom macroglobulinemia.

An overview of BTK inhibitors available as first-line therapy for Waldenström macroglobulinemia, and variables that impact treatment selection and the switching of agents throughout the course of therapy.

What pharmacists need to know about BTK inhibitor drug activity, dosing, and interactions in Waldenström macroglobulinemia.

The exciting therapies in the pipeline that are thought to target novel mechanisms in Waldenström macroglobulinemia.